FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/10/095642 [Registered on: 06/10/2025] Trial Registered Prospectively
Last Modified On: 06/10/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Homeopathy 
Study Design  Other 
Public Title of Study   Effectiveness Of Nux Vomica In The Homoeopathic Management Of Irritable Bowel Syndrome In Adults : An Experimental Non-Controlled Study 
Scientific Title of Study   Effectiveness Of Nux Vomica In The Homoeopathic Management Of Irritable Bowel Syndrome In Adults : An Experimental Non-Controlled Study 
Trial Acronym  Irritable Bowel Syndrome 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Achal Giri 
Designation  PG Student 
Affiliation  Dr G D Pol Foundation Ymt Homoeopathic Medical College Hospital And Pg Institute  
Address  Department of Homeopathic Materia Medica Dr G D Pol Foundation Ymt Homoeopathic Medical College Hospital And Pg Institute Institutional Area Sector 4 Kharghar Navi Mumbai 410210

Raigarh
MAHARASHTRA
410210
India 
Phone  7038639218  
Fax    
Email  achalgiri2000@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr C V Mehta 
Designation  Associate Professor 
Affiliation  Dr G D Pol Foundation Ymt Homoeopathic Medical College Hospital And Pg Institute  
Address  Dr G D Pol Foundation YMT Homoeopathic Medical College Hospital And Pg Institute Institutional Area Sector 4 Kharghar Navi Mumbai 410210

Raigarh
MAHARASHTRA
410210
India 
Phone  9869021226  
Fax    
Email  omcvm@yahoo.co.in  
 
Details of Contact Person
Public Query
 
Name  Dr Achal Giri 
Designation  PG Student 
Affiliation  DR G D Pol Foundation YMT Homoeopathic Medical College Hospital PG Institute 
Address  Dr G D Pol Foundation Ymt Homoeopathic Medical College Hospital And Pg Institute Institutional Area Sector 4 Kharghar Navi Mumbai 410210

Raigarh
MAHARASHTRA
410210
India 
Phone  7038639218  
Fax    
Email  achalgiri2000@gmail.com  
 
Source of Monetary or Material Support  
Dr G D Pol Foundation Ymt Homoeopathic Medical College Hospital And Pg Institute Institutional Area Sector 4 Kharghar Navi Mumbai 410210 
 
Primary Sponsor  
Name  DR ACHALGIRI 
Address  Dr G D Pol Foundation Ymt Homoeopathic Medical College Hospital And Pg Institute Institutional Area Sector 4 Kharghar Navi Mumbai 410210 
Type of Sponsor  Other [Self Sponsor] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
DR Achal Giri  Dr G D Pol Foundation Ymt Homoeopathic Medical College   Dr G D Pol Foundation Ymt Homoeopathic Medical College Hospital And Pg Institute Institutional Area Sector 4 Kharghar Navi Mumbai 410210
Raigarh
MAHARASHTRA 
7038639218

achalgiri2000@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
YMT Homoeopathic Medical college and PG institute   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K582||Mixed irritable bowel syndrome, (2) ICD-10 Condition: K582||Mixed irritable bowel syndrome,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Homeopathic management with Nux Vomica  To assess the patient pre- treatment and post treatment for Nux vomica in IBS on IBSSSS scale and to compare the pre- treatment score and post treatment score on IBSSSS scale 
Comparator Agent  NOT APPLICABLE  NOT APPLICABLE 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  50.00 Year(s)
Gender  Both 
Details  1 Patients fulfilling the Rome IV criteria and symptoms similar to drug picture of Nux vomica
2 Diagnosed patients of age group 18-50 years
3 Patients of all the genders
4 Patients from different socio-economic backgrounds will be considered.
5 Patients willing to give informed written consent.
 
 
ExclusionCriteria 
Details  1. Patients with alarm/red flag symptoms
a. Weight loss
b. Nocturnal symptoms
c. Family history of colon cancer
d. Anemia
e. Rectal bleeding
f. Fever.
2. Pregnant and lactating females.
3. Patients who are already taking other medications.
4. Patients who are immunocompromised
 
 
Method of Generating Random Sequence   Other 
Method of Concealment   Other 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Outcome will be assessed interms of :
1. Improved
2. Not improved 
d. Clinical outcome assessment will be done at base, 1 month, 3 months, 8 months and at termination of treatment 
 
Secondary Outcome  
Outcome  TimePoints 
Not Applicable  Not Applicable 
 
Target Sample Size   Total Sample Size="37"
Sample Size from India="37" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 1 
Date of First Enrollment (India)   20/10/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Introduction

 Irritable bowel syndrome IBS is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit, and with features of disordered defecation. It is coded in ICD 11 as DD91.0

 The prevalence of IBS within the community is between 10 percent and 25 percent the ratio of females to males in India reversed, i.e. 1 is to 3 to that of the Western countries.

The disorder is usually found in the age group of 15 to  50 years and may also occur in children and elderly.  In a study, prevalence of IBS in India was seen in 12.27 percent of the study population with male-to-female ratio of 1.44 to 1.

Homoeopathic science emphasizes on the psychosomatic aspects along with physical particulars. The study comprises of, management with the help of individualized homoeopathic remedy, when we study an Individual, we not only study the bodily configuration but also the intellectual and emotional as revealed to us though his reaction to the environment. Thus, the characteristics in physical and intellectual and emotional spheres, reveal the individual to us.

To ensure the good improvement, Homeopathy treats in a gentle and most harmless way with permanent restoration of health and annihilate the disease in a whole extent on easily comprehensible principles. Thus, Homeopathy gives more importance to the diseased individual than the disease itself. A homoeopathic physician considers the man as a whole. He considers the life as a trinity of body, mind and soul.

 There are various remedies in homoeopathy which are useful in treatment of IBS, most commonly used homeopathic remedies for IBS are nux vomica, sulphur, podophyllum, argentum nitricum, asafoetida, colocynthis, lycopodium, silicea etc. Nux vomica is being used for IBS over many years and is a great remedy for IBS, it demands more work in this area. Hence the study is undertaken to known the effectiveness of NUX VOMICA in cases of Irritable bowel syndrome.

OBJECTIVES

 1 Primary Objectives To study the effectiveness of Nux vomica in homoeopathic management of Irritable bowel syndrome in adults

 2 Other Objective To assess the patient pre- treatment and post treatment for IBS on IBSSSS scale and to compare the pre- treatment score and post treatment score on IBSSSS scale

3 Other Objective To study drug picture of nux vomicas

METHODOLOGY

I STUDY DESIGN An Experimental non-controlled study.

2 STUDY SETTING Cases will be collected from the OPD of the institute.

3  STUDY POPULATION  Diagnosed patients of irritable bowel syndrome of age group 18 to 50 years of age and those fulfilling the Rome IV criteria with absence of alarm symptoms.

 4  DURATION OF STUDY

 a. Duration of study  18 months

 b. Duration of each case Each case will be studied for 8 months or until remission of symptoms

 c. Duration of follow up Each case will be followed up after 15 days or as and when required

d. Clinical outcome assessment will be done at base, 1 month, 3 months, 8 months and at termination of treatment

5 METHODS OF SELECTION OF STUDY SUBJECT  ELIGIBILITY CRITERIA

A. INCLUSION CRITERIA

1. Patients fulfilling the Rome IV criteria and symptoms similar to drug picture of nux vomica

2. Diagnosed patients of age group 18 to 50 years

3. Patients of all the genders

 4. Patients from different socio economic backgrounds will be considered.

5. Patients willing to give informed written consent.

B. EXCLUSION CRITERIA

1. Patients with alarm ,red flag symptoms

a. Weight loss

b. Nocturnal symptoms

c. Family history of colon cancer

 d. Anemia

e. Rectal bleeding

 f. Fever.

2. Pregnant and lactating females.

3. Patients who are already taking other medications.

4. Patients who are immunocompromised

C. SUBJECT WITHDRAWAL CRITERIA

1 Patients who are not willing to continue further, for homoeopathic treatment during ongoing research study

2 Patients with an irregular follow up

3 In medical and surgical emergencies

4 In case of alarm symptoms if any occur during the study.

6  METHOD OF SELECTION OF COMPARISON OR CONTROL GROUP AND MATCHING CRITERIA Not Applicable

7 OPERATIONAL DEFINITION: Irritable bowel syndrome IBS is a functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit and with features of disordered defecation

 It is coded in ICD 11 as DD91.0

8 SPECIFICATION OF INSTRUMENTS AND RELATED MEASUREMENTS: Entire study will be single examiner study.

 1. Case taking Proforma

2. Outcome assessment tool Irritable Bowel Syndrome severity scoring scale IBSSSS Improvement of the patient will be determined from the help of pre validated scale

Classification of IBS severity using this scale is

     

 Outcome assessment criteria

The Outcome will be assessed in terms of:

Improved If  Irritable Bowel Syndrome severity scoring scale is reduced than the previous Irritable Bowel Syndrome severity scoring scale., after taking homeopathic medicines.

 Not Improved If  Irritable Bowel Syndrome severity scoring scale remains same after taking homeopathic medicines

 

Outcome assessment criteria

The Outcome will be assessed in terms of

Improved If  Irritable Bowel Syndrome severity scoring scale is reduced than the previous Irritable Bowel Syndrome severity scoring scale., after taking homeopathic medicines.

Not Improved  If  Irritable Bowel Syndrome severity scoring scale remains same after taking homeopathic medicines.

 SAMPLE SIZE

Though the sample size calculated is 31, but in this study minimum 40 sample sizeis taken

SAMPLING TECHNIQUE Non Probability Purposive Sampling.

3 METHODS OF DATA COLLECTION RELEVANT TO OBJECTIVE

a.      A. Non probability purposive sampling based on Inclusion and Exclusion criteria.

  B. 40 cases will be recorded from outpatient department of the  institute.

C. Detailed homoeopathic case taking will be done as per the proforma  will be used for collecting and analysing data prepared to arrive at the  appropriate similimum.

D. Depending on the clinical presentation of the patient and totality erected, the patient will be administered indicated individualised homoeopathic medicine.

E. Posology will be selected as per the requirement of the case.

 

4 STUDY INSTRUMENT  DATA COLLECTION TOOLS

 

1. Complete Homeopathic Case taking proforma to form Totality with Special Emphasis on Individualizing case

2. IBSSSS Scale will be used to assess the severity before and after  the treatment  

3. Appropriate reference books like Homoeopathic Materia Medica, Medicine ,Surgery books, Pathology books, different Homoeopathic Journals, research paper will be considered

  4. Appropriate Software will be used for repertorization of case

5 DATA MANAGEMENT AND ANALYSIS PROCEDURE

1.Framing of totality of symptoms  Will be done as per the principles of homoeopathy.

2.Selection of remedy  Homoeopathic remedy after referring Materia Medica.

3.The Posology Appropriate potency will be selected based on susceptibility of each case. Potency will be changed when required.

4.Duration of study

a.      Duration of study  18 months

b.      Duration of each case Each case will be studied for 8 months  or until remission of symptoms.

c.      Duration of follow up Each case will be followed up after 15 days or as and when required.

d.      Clinical outcome assessment will be done at base, 1 month, 3 months, 8 months and at termination of treatment

 2. Normality of numerical data will be checked using Shapiro Wilk test or    Kolmogorov Smirnov test. Depending on the normality of data, statistical tests will be determined

 
Close